ATE556707T1 - Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits - Google Patents
Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizitsInfo
- Publication number
- ATE556707T1 ATE556707T1 AT04759288T AT04759288T ATE556707T1 AT E556707 T1 ATE556707 T1 AT E556707T1 AT 04759288 T AT04759288 T AT 04759288T AT 04759288 T AT04759288 T AT 04759288T AT E556707 T1 ATE556707 T1 AT E556707T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- phosphodiesesterase
- treatment
- cognitive deficit
- cognitive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/410,508 US20040224316A1 (en) | 2000-08-10 | 2003-04-08 | Augmented cognitive training |
PCT/US2004/010876 WO2004091609A2 (en) | 2001-08-10 | 2004-04-08 | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE556707T1 true ATE556707T1 (de) | 2012-05-15 |
Family
ID=37416211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04759288T ATE556707T1 (de) | 2003-04-08 | 2004-04-08 | Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits |
Country Status (8)
Country | Link |
---|---|
US (2) | US20040224316A1 (de) |
EP (4) | EP2116240B1 (de) |
JP (1) | JP4833834B2 (de) |
AT (1) | ATE556707T1 (de) |
CA (1) | CA2521839C (de) |
ES (3) | ES2509093T3 (de) |
HK (2) | HK1087351A1 (de) |
WO (1) | WO2004091609A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
US9931318B2 (en) | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
PT1355669E (pt) | 2000-08-10 | 2012-01-02 | Cold Spring Harbor Lab | Treino cognitivo aumentado |
US8975216B2 (en) * | 2006-03-30 | 2015-03-10 | Pacific Biosciences Of California | Articles having localized molecules disposed thereon and methods of producing same |
MX2008014713A (es) * | 2006-05-19 | 2009-04-17 | Helicon Therapeutics Inc | Inhibidores de fosfodiesterasa 4 para rehabilitacion cognitiva y motora. |
CN101679254A (zh) * | 2007-03-12 | 2010-03-24 | 比奥里波克斯公司 | 用于炎症治疗的哌啶酮类 |
GB0722769D0 (en) * | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
AU2008254905A1 (en) * | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of treating cognitive disorders by inhibition of Gpr12 |
BRPI0811623A2 (pt) * | 2007-05-15 | 2014-11-11 | Helicon Therapeutics Inc | Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna) |
JP5049713B2 (ja) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置 |
AU2009270697A1 (en) * | 2008-07-18 | 2010-01-21 | Dart Neuroscience Llc | Methods and systems for evaluating memory agents |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
US20150050626A1 (en) * | 2013-03-15 | 2015-02-19 | Dart Neuroscience, Llc | Systems, Methods, and Software for Improving Cognitive and Motor Abilities |
WO2015144598A1 (en) * | 2014-03-28 | 2015-10-01 | Algiax Pharmaceuticals Gmbh | Treatment of cognitive disorders |
WO2022156727A1 (zh) | 2021-01-21 | 2022-07-28 | 浙江养生堂天然药物研究所有限公司 | 治疗肿瘤的组合物及方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5479508A (en) * | 1991-05-22 | 1995-12-26 | Zenith Electronics Corp. | Method of operating a pay per view television system |
US5547979A (en) * | 1992-03-30 | 1996-08-20 | Smithkline Beecham | TNF inhibition |
EP0633776B1 (de) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen |
US5681735A (en) | 1992-04-10 | 1997-10-28 | Fox Chase Cancer Center | Transcription control element for increasing gene expression in myoblasts |
NZ291507A (en) * | 1994-08-29 | 1997-12-19 | Yamanouchi Pharma Co Ltd | 1,8-naphthyridine derivatives; medicaments |
US5619249A (en) * | 1994-09-14 | 1997-04-08 | Time Warner Entertainment Company, L.P. | Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs |
WO1996011270A1 (en) | 1994-10-07 | 1996-04-18 | Cold Spring Harbor Laboratory | Cloning and characterizing of genes associated with long-term memory |
US5929223A (en) * | 1994-10-07 | 1999-07-27 | Cold Spring Harbor Laboratory | Cloning and characterizing of genes associated with long-term memory |
US5652749A (en) * | 1995-02-03 | 1997-07-29 | International Business Machines Corporation | Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream |
US5793410A (en) * | 1995-05-26 | 1998-08-11 | Hyundai Electronics America | Video pedestal network |
US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
EP0936923B1 (de) * | 1996-11-15 | 2003-12-17 | Kennedy Institute Of Rheumatology | UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE |
NZ336573A (en) * | 1997-01-15 | 2000-10-27 | Byk Gulden Lomberg Chem Fab | 4-Phenyl substituted phthalazin-1-one derivatives useful for treating airway disorders |
US6458829B1 (en) | 1998-09-09 | 2002-10-01 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactones and analogs thereof and uses related thereto |
IT1303272B1 (it) | 1998-10-29 | 2000-11-06 | Zambon Spa | Derivati triciclici inibitori della fosfodiesterasi 4 |
CA2364653A1 (en) | 1999-02-25 | 2000-08-31 | Merck Frosst Canada & Co. | Pde iv inhibiting compounds, compositions and methods of treatment |
US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
EP2258689A1 (de) | 2000-03-16 | 2010-12-08 | Biolipox AB | Benzylierte PDE4-Inhibitoren |
PT1355669E (pt) * | 2000-08-10 | 2012-01-02 | Cold Spring Harbor Lab | Treino cognitivo aumentado |
ATE463739T1 (de) * | 2002-08-19 | 2010-04-15 | Helicon Therapeutics Inc | Screening-verfahren für kognitive erweiterungsvorrichtungen |
-
2003
- 2003-04-08 US US10/410,508 patent/US20040224316A1/en not_active Abandoned
-
2004
- 2004-04-08 ES ES11156095.9T patent/ES2509093T3/es not_active Expired - Lifetime
- 2004-04-08 EP EP09166577A patent/EP2116240B1/de not_active Expired - Lifetime
- 2004-04-08 CA CA2521839A patent/CA2521839C/en not_active Expired - Fee Related
- 2004-04-08 EP EP09178328A patent/EP2156831B1/de not_active Expired - Lifetime
- 2004-04-08 EP EP11156095.9A patent/EP2340831B1/de not_active Expired - Lifetime
- 2004-04-08 WO PCT/US2004/010876 patent/WO2004091609A2/en active Application Filing
- 2004-04-08 EP EP04759288A patent/EP1631281B1/de not_active Expired - Lifetime
- 2004-04-08 JP JP2006509825A patent/JP4833834B2/ja not_active Expired - Fee Related
- 2004-04-08 ES ES09166577T patent/ES2403333T3/es not_active Expired - Lifetime
- 2004-04-08 AT AT04759288T patent/ATE556707T1/de active
- 2004-04-08 ES ES09178328T patent/ES2403283T3/es not_active Expired - Lifetime
-
2006
- 2006-06-29 US US11/479,185 patent/US8097647B2/en not_active Expired - Fee Related
- 2006-08-21 HK HK06109214.5A patent/HK1087351A1/xx not_active IP Right Cessation
- 2006-08-21 HK HK12100142.3A patent/HK1159514A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1159514A1 (en) | 2012-08-03 |
EP2340831A1 (de) | 2011-07-06 |
ES2403283T3 (es) | 2013-05-17 |
HK1087351A1 (en) | 2006-10-13 |
US8097647B2 (en) | 2012-01-17 |
WO2004091609A2 (en) | 2004-10-28 |
JP2006524243A (ja) | 2006-10-26 |
JP4833834B2 (ja) | 2011-12-07 |
US20060247252A1 (en) | 2006-11-02 |
WO2004091609A3 (en) | 2007-08-16 |
US20040224316A1 (en) | 2004-11-11 |
ES2509093T3 (es) | 2014-10-17 |
EP2156831B1 (de) | 2013-02-27 |
EP2156831A1 (de) | 2010-02-24 |
CA2521839C (en) | 2014-08-05 |
EP2116240B1 (de) | 2013-02-27 |
ES2403333T3 (es) | 2013-05-17 |
EP1631281A2 (de) | 2006-03-08 |
EP2116240A1 (de) | 2009-11-11 |
EP2340831B1 (de) | 2014-09-10 |
CA2521839A1 (en) | 2004-10-28 |
EP1631281B1 (de) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1087351A1 (en) | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit | |
WO2005048953A3 (en) | Amide derivatives as kinase modulators | |
DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
ATE286028T1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
DE60122368D1 (de) | Verwendung von Gaboxadol zur Behandlung von premenstruelle Störung, postnatal Depression oder postmenopausal-bedingte-dysphorische Störung | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
WO2007028151A3 (en) | Surgical devices and related methods thereof | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
DE602005019341D1 (de) | System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser | |
DE602004021847D1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
DE60231507D1 (de) | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten | |
WO2009015369A3 (en) | Isophthalamide derivatives inhibiting beta-secretase activity | |
BRPI0417108A (pt) | métodos de tratamento de rejeições de transplantes em pacientes | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
DE60219687D1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
AU2003215190A8 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
ATE443262T1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen | |
DE112006001557A5 (de) | Verfahren zur Abformung des Kiefers bzw. der Kiefersituation bei der zahnmedizinischen Behandlung von Patienten |